Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results

Concord Drugs Financial Results

Concord Drugs Limited approved its audited financial results for the year ended March 2026. Consolidated total revenue surged significantly to ₹78.77 Crore, demonstrating strong performance.

Key figures
Value₹78.77 Cr
Source

BSE filing, NSE: CONCORD. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Concord Drugs Ltd: key numbers

Share price
₹64.01
Market cap
₹84.33 Cr
Revenue (annual)
₹78.74 Cr
Net profit (annual)
₹1.06 Cr
P/E (TTM)
41.1×Sector 46.1×
Promoter holding
45.08%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Concord Drugs Ltd

All →

Other financial results announcements

All →